Efficacy and safety of disitamab vedotin in combination with immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.

Introduction: Disitamab Vedotin (DV, RC48, or RC48-ADC) is a novel humanized antibody-drug conjugate (ADC), which is based on human epidermal growth factor receptor 2 antibody (anti-HER2, or hertuzumab) coupled with monomethyl auristatin E (MMAE). This study aims to evaluate the efficacy and safety of RC48-ADC in combination with programmed cell death protein 1 (PD-1) inhibitors for treatment of locally advanced or metastatic urothelial carcinoma (la/mUC) patients.

Patients And Methods: This is a retrospective and real-world investigation originated from an enrollment of locally advanced or mUC patients underwent treatments with RC48-ADC in combination with PD-1 inhibitors in two hospitals, between August 2022 and July 2024.

Association between the neutrophil-to-high-density lipoprotein cholesterol ratio with kidney stone risk: a cross-sectional study.

Objective: Kidney stones are a major issue for public health worldwide. Discovering potential clues in identifying at-risk individuals is essential for early detection and timely treatment. This study explores the relationship of the neutrophil-to-high-density lipoprotein cholesterol ratio (NHR) with the risk of kidney stones in U.